Structures of PKA-phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy

  1. Juan Qin
  2. Jingfeng Zhang
  3. Lianyun Lin
  4. Omid Haji-Ghassemi
  5. Zhi Lin
  6. Kenneth J Woycechowsky
  7. Filip Van Petegem
  8. Yan Zhang  Is a corresponding author
  9. Zhiguang Yuchi  Is a corresponding author
  1. Tianjin University, China
  2. Chinese Academy of Sciences, China
  3. University of British Columbia, Canada

Abstract

Several mutations identified in phospholamban (PLN) have been linked to familial dilated cardiomyopathy (DCM) and heart failure, yet the underlying molecular mechanism remains controversial. PLN interacts with sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) and regulates calcium uptake, which is modulated by the protein kinase A (PKA)-dependent phosphorylation of PLN during the fight-or-flight response. Here, we present the crystal structures of the catalytic domain of mouse PKA in complex with wild-type and DCM-mutant PLNs. Our structures, combined with the results from other biophysical and biochemical assays, reveal a common disease mechanism: the mutations in PLN reduce its phosphorylation level by changing its conformation and weakening its interactions with PKA. In addition, we demonstrate that another more ubiquitous SERCA-regulatory peptide, called another-regulin (ALN), shares a similar mechanism mediated by PKA in regulating SERCA activity.

Data availability

Diffraction data have been deposited in PDB under the accession code: PKAc-WT PLN (PDB 7E0Z); PKAc-PLN R9C (PDB 7E11); PKAc-PLN A11E (PDB 7E12).

The following data sets were generated

Article and author information

Author details

  1. Juan Qin

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Jingfeng Zhang

    Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Lianyun Lin

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Omid Haji-Ghassemi

    Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada
    Competing interests
    The authors declare that no competing interests exist.
  5. Zhi Lin

    School of Life Sciences, Tianjin University, Tianjin, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Kenneth J Woycechowsky

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Filip Van Petegem

    Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada
    Competing interests
    The authors declare that no competing interests exist.
  8. Yan Zhang

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    For correspondence
    yan.zhang@tju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
  9. Zhiguang Yuchi

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    For correspondence
    yuchi@tju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2595-9106

Funding

National Natural Science Foundation of China (32022073)

  • Zhiguang Yuchi

National Natural Science Foundation of China (31972287)

  • Zhiguang Yuchi

Natural Science Foundation of Tianjin City (19JCYBJC24500)

  • Zhiguang Yuchi

Canadian Institutes of Health Research (PJT-159601)

  • Filip Van Petegem

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Kurt Beam, University of Colorado Anschutz Medical Campus, United States

Version history

  1. Received: November 8, 2021
  2. Preprint posted: November 16, 2021 (view preprint)
  3. Accepted: March 16, 2022
  4. Accepted Manuscript published: March 17, 2022 (version 1)
  5. Version of Record published: March 31, 2022 (version 2)
  6. Version of Record updated: January 5, 2023 (version 3)

Copyright

© 2022, Qin et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,661
    Page views
  • 233
    Downloads
  • 3
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Juan Qin
  2. Jingfeng Zhang
  3. Lianyun Lin
  4. Omid Haji-Ghassemi
  5. Zhi Lin
  6. Kenneth J Woycechowsky
  7. Filip Van Petegem
  8. Yan Zhang
  9. Zhiguang Yuchi
(2022)
Structures of PKA-phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy
eLife 11:e75346.
https://doi.org/10.7554/eLife.75346

Share this article

https://doi.org/10.7554/eLife.75346

Further reading

    1. Biochemistry and Chemical Biology
    Jake W Anderson, David Vaisar ... Natalie G Ahn
    Research Article

    Activation of the extracellular signal-regulated kinase-2 (ERK2) by phosphorylation has been shown to involve changes in protein dynamics, as determined by hydrogen-deuterium exchange mass spectrometry (HDX-MS) and NMR relaxation dispersion measurements. These can be described by a global exchange between two conformational states of the active kinase, named ‘L’ and ‘R,’ where R is associated with a catalytically productive ATP-binding mode. An ATP-competitive ERK1/2 inhibitor, Vertex-11e, has properties of conformation selection for the R-state, revealing movements of the activation loop that are allosterically coupled to the kinase active site. However, the features of inhibitors important for R-state selection are unknown. Here, we survey a panel of ATP-competitive ERK inhibitors using HDX-MS and NMR and identify 14 new molecules with properties of R-state selection. They reveal effects propagated to distal regions in the P+1 and helix αF segments surrounding the activation loop, as well as helix αL16. Crystal structures of inhibitor complexes with ERK2 reveal systematic shifts in the Gly loop and helix αC, mediated by a Tyr-Tyr ring stacking interaction and the conserved Lys-Glu salt bridge. The findings suggest a model for the R-state involving small movements in the N-lobe that promote compactness within the kinase active site and alter mobility surrounding the activation loop. Such properties of conformation selection might be exploited to modulate the protein docking interface used by ERK substrates and effectors.

    1. Biochemistry and Chemical Biology
    Anne E Hultgren, Nicole MF Patras, Jenna Hicks
    Feature Article

    Organizations that fund research are keen to ensure that their grant selection processes are fair and equitable for all applicants. In 2020, the Arnold and Mabel Beckman Foundation introduced blinding to the first stage of the process used to review applications for Beckman Young Investigator (BYI) awards: applicants were instructed to blind the technical proposal in their initial Letter of Intent by omitting their name, gender, gender-identifying pronouns, and institutional information. Here we examine the impact of this change by comparing the data on gender and institutional prestige of the applicants in the first four years of the new policy (BYI award years 2021–2024) with data on the last four years of the old policy (2017–2020). We find that under the new policy, the distribution of applicants invited to submit a full application shifted from those affiliated with institutions regarded as more prestigious to those outside of this group, and that this trend continued through to the final program awards. We did not find evidence of a shift in the distribution of applicants with respect to gender.